Severe aplastic anaemia is a life-threatening bone marrow failure condition requiring aggressive treatment with combination immunosuppressive therapy plus a thrombopoietin receptor agonist. Dallas's UT Southwestern and Baylor University Medical Center manage these complex cases, and Rompag 50mg provides a high-dose option for both aplastic anaemia and refractory ITP at significantly reduced cost.
Rompag is used at doses up to 150mg daily in aplastic anaemia patients undergoing combination immunosuppressive therapy with anti-thymocyte globulin and cyclosporine — clinical trials showed adding Eltrombopag to standard treatment produced complete haematologic responses in over 90% of previously untreated patients.
Dallas hospital pharmacies can access Rompag at significantly lower cost than brand Revolade, with full WHO-GMP certification and USFDA-compliant documentation.
Rompag is used at doses up to 150mg daily in aplastic anaemia patients undergoing combination immunosuppressive therapy with anti-thymocyte globulin and cyclosporine — clinical trials showed adding Eltrombopag to standard treatment produced complete haematologic responses in over 90% of previously untreated patients.
Dallas hospital pharmacies can access Rompag at significantly lower cost than brand Revolade, with full WHO-GMP certification and USFDA-compliant documentation.
Why is Eltrombopag combined with other immunosuppressive drugs for aplastic anaemia rather than used alone?Severe aplastic anaemia involves the immune system attacking and destroying bone marrow stem cells, so treatment needs to address both the destruction (via immunosuppression with anti-thymocyte globulin and cyclosporine) and stimulate new blood cell production (via Eltrombopag's effect on the thrombopoietin receptor). Used alone, Eltrombopag wouldn't address the underlying autoimmune process. The three-drug combination achieves substantially higher response rates than immunosuppression alone, which is why it has become the modern standard of care for this condition